NEW HAVEN, Conn., March 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company ...
TORONTO, October 15, 2025--(BUSINESS WIRE)--ProteinQure announced new preclinical results today, demonstrating efficient delivery of small interfering RNA (siRNA) to the central nervous system (CNS) ...
−Preclinical Proof of Concept for Oral Delivery Achieved, Demonstrating Robust, Dose-Dependent Silencing of Liver-Expressed Target in Rodents, with Durability Profile Similar to Subcutaneous ...
MARSEILLE, France, and SEOUL, South Korea, Feb. 3, 2026 -- Vect-Horus, a France-based biotechnology company, and OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, ...
Alnylam Pharmaceuticals will partner with Regeneron Pharmaceuticals to discover, develop, and commercialize RNA interference (RNAi) therapeutics for diseases of the eye and CNS—as well as advance ...
OliX Pharmaceuticals said on the 11th that it signed an option contract with Swedish biotech company "Key2Brain AB" to evaluate drug delivery technology and consider a technology in-license for ...
Partnership launched under MTEA to evaluate the potential of Vect-Horus technology to deliver siRNAs into the CNS Assessment of BBB shuttle-siRNA compatibility, CNS delivery efficiency, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results